Presentation will showcase Company's patented iSPERSE™ technology and positive topline results from Phase 1 study of PUR3100 for acute migraine Pulmatrix plans to submit an IND in mid-2023 for a ...
OCALA, Fla., Feb. 17, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple ...
SAN DIEGO, Calif. — Team members with the U.S. Army Medical Materiel Development Activity joined thousands of biotechnology industry experts from across the world for the Biotechnology Innovation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results